The role of repaglinide in the treatment of secondary sulphonylureas failure

Abstract EN

Background : About [20 %-25 %] of type 2 diabetes patients are unresponsive to sulphonylureas (primary failure) and an additional 5 %-10 % of patients each year become unresponsive (secondary failure).

Objective : Assessment of the efficacy of repaglinide in the treatment of secondary sulphonylurea failure.

Patients and Method : 48 patients with type 2 DM who failed to respond to a combination of full dose of glibenclamide and metformin are put on combination of repaglinide (3 mg / day) and metformin and blood glucose is monitored for 9-11 weeks.

Results : 12 patients [25 %] out of 48 patients with secondary sulphonylureas failure obtained good glycemic control with repaglinide.

Conclusion : Repaglinide can induce good glycemic control in some patients with secondary sulphonylureas failure.